Last reviewed · How we verify
Corticotropin-Releasing Factor (Human) (CORTICORELIN)
At a glance
| Generic name | CORTICORELIN |
|---|---|
| Target | Corticotropin-releasing factor receptor 1 |
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Diagnosis of Hypercortisolism
Common side effects
- Flushing of face, neck, and upper chest
- Dyspnea
- Tachycardia
- Urticaria
- Wheezing
- Angioedema
- Chest compression or tightness
- Hypotension
- Urge to take a deep breath
- Transient flushing
- Feelings of dyspnea
Serious adverse events
- Asystole requiring resuscitation
- Precipitous fall in blood pressure and pulse rate
- Loss of consciousness (absence-like)
- Grand mal epileptic seizure
- Significant decrease in blood pressure
- Significant increase in heart rate
Key clinical trials
- CRF2 Agonist for the Treatment of Worsening Heart Failure (PHASE2)
- Chromosome 18 Clinical Research Center
- The Effect of Sulfasalazine on CRH Levels in Pregnant Women (PHASE2)
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women (EARLY_PHASE1)
- Hormonal Mechanisms of Sleep Restriction - Axis Study (PHASE1)
- Reducing Pregnancy Risks: The Mastery Lifestyle Intervention (NA)
- Imaging CRF X NOP Interactions in CUD (EARLY_PHASE1)
- Cardiorespiratory Fitness Training in Patients with Incomplete Spinal Cord Injury (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |